Pulmonary translocation of ultrafine carbon particles in COPD and IPF patients

Inhal Toxicol. 2022;34(1-2):14-23. doi: 10.1080/08958378.2021.2019859. Epub 2021 Dec 30.

Abstract

Objective: Epidemiological studies indicate association between elevated air pollution and adverse health effects. Several mechanisms have been suggested, including translocation of inhaled ultrafine carbon (UFC) particles into the bloodstream. Previous studies in healthy subjects have shown no significant pulmonary translocation of UFC-particles. This study aimed to assess if UFC-particles translocate from damaged alveolar compartment in subjects suffering from chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Methods: Eleven COPD and nine IPF subjects were exposed to a 100 nm UFC-particle-aerosol labeled with Indium-111. Activity in the body was followed up for 10 days using gamma camera planar-imaging as well as in blood and urine samples.

Results: The pulmonary central to periphery activity ratio was significantly higher for COPD as compared to IPF subjects at exposure, 1.8 and 1.4, respectively and remained constant throughout the test period. Ten days after exposure, the estimated median pulmonary translocation of UFC particles was 22.8 and 25.8% for COPD and IPF, respectively. Bound activity was present in blood throughout the test period, peaking at 24-h postinhalation with a median concentration of 5.6 and 8.9 Bq/ml for the COPD and IPF, respectively. Median bound activity excreted in urine (% of inhaled) after 10 days was 1.4% in COPD and 0.7% in IPF. Activity accumulation in liver and spleen could not be demonstrated.

Conclusions: Our results suggest that UFC particles leak through the damaged alveolar barrier to the bloodstream in COPD and IPF patients probably distributing in a wide spectrum of whole-body tissues.

Keywords: Ultrafine carbon particles; air pollution; chronic obstructive pulmonary disease (COPD); idiopathic pulmonary fibrosis (IPF); nano particles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carbon / metabolism
  • Humans
  • Idiopathic Pulmonary Fibrosis* / diagnostic imaging
  • Idiopathic Pulmonary Fibrosis* / metabolism
  • Lung / metabolism
  • Particulate Matter / metabolism
  • Particulate Matter / toxicity
  • Pulmonary Disease, Chronic Obstructive*

Substances

  • Particulate Matter
  • Carbon